Global medical technology company Medtronic has revealed new data from the High Risk Study of the CoreValve US Pivotal Trial.

The trial is said to have demonstrated superior clinical outcomes for transcatheter aortic valve replacement (TAVR) with the CoreValve System as compared to surgical aortic valve replacement (SAVR) out to three years.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the trial, which included 407 patients, 228 were treated with TAVR while 179 patients were administered with SAVR treatment.

"Most importantly, the new data supports the viability of TAVR out to three years with no signal of a significant increase in mean gradient or aortic regurgitation."

Patients treated with TAVR have exhibited better result compared to surgery for the combined endpoint of all-cause mortality or stroke and for all stroke.

TAVR has registered a lower all-cause mortality compared to SAVR-treated patients.

University of Michigan Frankel Cardiovascular Centre Herbert Sloan Collegiate Professor of Cardiac Surgery Michael Deeb said: "It’s reassuring to see that the CoreValve High Risk Study continues to show that TAVR is superior to surgery at three years for the combined endpoint of mortality and stroke, which has the most important impact on patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Most importantly, the new data supports the viability of TAVR out to three years with no signal of a significant increase in mean gradient or aortic regurgitation."

The supra-annular design of the CoreValve System has facilitated an improved valve performance in the TAVR group with sustained single-digit gradients (measurement of blood flow through the valve) which was lower than surgery patients during the course of the trial.

The CoreValve System also ensured safety to surgery in these patients with lowered rates of major adverse cardiovascular and cerebrovascular events (MACCE) in the CoreValve group.

In 2014, the CoreValve System has been approved by the US Food and Drug Administration for patients at extreme risk and high-risk for surgery and happens to be the first TAVR device approved in the US for valve-in-valve procedures in both high and extreme risk patients with failed surgical valves.

After being the first TAVR device to receive CE Mark in 2007, the CoreValve System is utilised by more than 100,000 patients across over 60 countries.